在患有脏或肝功能损害的患者中,化疗诱导的血液毒性
Kelly Nies1, Robin Vernooij1,2,3, Lot Devriese4
1Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.
Pharmaceutics
|October 29, 2025
概括
患有或肝功能障碍的患者面临更高的化学疗法诱导的严重血液毒性风险,如中性质减退,血小板减退和贫血. 这项研究强调了在这些患者群体中可能会增加风险的特定化疗方案.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 血液毒性 (中性质减退,血小板减退,贫血) 是常见的化疗并发症.
- 或肝功能障碍可能会改变药物暴露,可能会加剧这些毒性.
- 了解这些关联对于在有器官功能障碍的患者中安全地进行化疗至关重要.
研究的目的:
- 评估和肝功能障碍之间的关联以及化疗期间血液毒性的发生率.
- 为了确定与脏或肝功能受损患者中毒性风险增加相关的特定化疗方案.
- 提供数据,可以为脆弱患者群体的化学疗法的未来剂量调整提供信息.
主要方法:
- 一个单一中心的回顾性队列研究,利用乌得勒支患者导向数据库 (UPOD).
- 包括2011年至2024年间的化疗管理,重点关注至少10名脏或肝功能障碍患者的治疗方案.
- 考克斯的比例危险模型被用来分析器官衰竭与3级以上的血液毒性之间的关联.
主要成果:
- 功能障碍与3级以上中性质衰竭 (HR:1.43),血小板衰竭 (HR:1.46) 和贫血 (HR:1.66) 的风险增加显著相关.
- 肝功能障碍也显示出与中性质减退 (HR:1.25) 血栓细胞减退 (HR:1.33) 和贫血 (HR:1.62) 的风险增加的显著关联.
- 特定的药物,如环胺,埃托波西德,梅尔法兰和甲醇,根据器官损伤的类型,表现出不同的毒性风险.
结论:
- 和肝功能不良都会大大增加化学疗法引起的严重血液毒性的风险.
- 某些化疗方案被确定为患有器官功能障碍的患者的高风险.
- 需要进一步的多中心研究来完善脏或肝功能障碍患者的化疗剂量指南.
相关概念视频
Renal Failure: Dose Adjustments
429
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
429
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
205
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
205
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
248
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
232
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
232


